> ## Content Index > Fetch the complete content index at: https://brief.sharpertrades.com/llms.txt > Use this file to discover other available public pages before exploring further. # Novartis Hit by Triple Clinical Setback as Pipeline Risk Rattles Investors - URL: https://brief.sharpertrades.com/novartis-hit-by-triple-clinical-setback-as-pipeline-risk-rattles-investors/ - Published: 2026-09-08T16:30:00.000Z - Updated: 2026-09-08T17:18:39.000Z - Description: Novartis shares plunged after del-desiran failed a Phase III trial, compounding setbacks for pelacarsen and rap-cel and raising concerns about the drugmaker’s pipeline as key products face patent pressure. - Author: Luca Moschini - Tags: Innovation & Tech, Business Trends, Price Action ### Pipeline Setbacks Put Novartis’ Growth Engine Under Scrutiny Novartis (NVS) shares fell roughly 14% Tuesday, pacing toward their steepest drop on record, after experimental neuromuscular drug del-desiran failed to meet the primary endpoint in the Phase III HARBOR study. The result followed a Phase III failure for cardiovascular drug pelacarsen and safety-related pauses involving experimental cell therapy rap-cel. The concentration of setbacks within days shifted the market reaction beyond any single drug candidate. Investors are reassessing the value of several important development programs as Novartis works to offset falling sales of Entresto and future patent expirations. The company nevertheless maintained its target for average annual sales growth of 5% to 6% through 2030. --- ### Key Points - Del-desiran failed to significantly improve the Phase III HARBOR trial's primary measure, adding another late-stage setback for Novartis. - Pelacarsen separately failed to reduce cardiovascular risk despite lowering Lp(a), while eight of 10 rap-cel studies were paused following three patient deaths. - Novartis maintained its **5% to 6% average annual sales growth target through 2030**, but the setbacks intensified scrutiny of its pipeline and recent acquisitions. --- ## Del-Desiran Failure Hits a Key Acquired Asset The immediate catalyst for Tuesday's NVS stock selloff was the Phase III HARBOR study of del-desiran in myotonic dystrophy type 1. The approximately 150-patient, 54-week study evaluated whether the treatment could significantly improve video hand opening time, which measures how quickly patients can open their hand after making a fist. Del-desiran did not demonstrate a statistically significant improvement over placebo on that primary endpoint. Novartis said there was evidence of activity across secondary endpoints and exploratory analyses and that safety findings were generally consistent with prior data. The company is evaluating the full HARBOR dataset and plans to discuss the results with health authorities before determining the program's development path. The financial significance extends beyond a single clinical program. Del-desiran was a centerpiece of Novartis' approximately $12 billion acquisition of Avidity Biosciences and had been viewed as a potential multibillion-dollar product. The acquisition also brought additional antibody oligonucleotide conjugate therapies into the company's neuromuscular pipeline. The acquired platform remains active, including delpacibart zotadirsen, which is under FDA Priority Review for DMD44, and delpacibart braxlosiran, for which regulatory discussions are planned in FSHD. ## Why Did Novartis Stock Fall So Sharply? The market was responding to a sequence of clinical setbacks rather than the HARBOR result alone. Days earlier, Novartis reported that pelacarsen failed the primary endpoint of the Phase III Lp(a)HORIZON study. The 8,323-patient trial tested the cardiovascular treatment in people with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease. Pelacarsen successfully reduced Lp(a), but that biomarker improvement did not translate into a significant reduction in the trial's composite measure of cardiovascular death, non-fatal heart attack, non-fatal stroke and urgent coronary revascularization requiring hospitalization compared with placebo. The result was significant because it raised questions about whether reducing Lp(a) produces additional clinical benefits for patients already receiving standard treatment. Full trial data, including additional analyses, have not yet been disclosed and are expected to be presented at a medical congress. The third setback involved rapcabtagene autoleucel, or rap-cel. Novartis paused eight of 10 studies involving the experimental cell therapy following three patient deaths linked to a rare autoimmune reaction. Together, the events reduced the risk-adjusted value investors could assign to several development programs within a matter of days. NVS shares fell roughly 14% Tuesday, bringing the stock close to where it began the year. ## What Matters Next for the Novartis Pipeline? The next phase centers on clinical details, regulatory discussions and the performance of Novartis' remaining pipeline. For del-desiran, Novartis is reviewing secondary and exploratory findings and plans to engage health authorities about the appropriate development path. The undisclosed magnitude and statistical significance of those additional results remain important to evaluating the program. For pelacarsen, full subgroup and secondary-endpoint data could provide more information about why lower Lp(a) levels failed to produce the targeted cardiovascular outcome in the overall study population. The rap-cel safety investigation represents another unresolved issue following the suspension of most studies involving the therapy. There are also successful programs elsewhere in the pipeline. Remibrutinib recently succeeded in two Phase III trials in relapsing multiple sclerosis, while MRT-6160 has entered a Phase II study in Sjögren's disease. Novartis is scheduled to hold its capital markets day in November. Meanwhile, the company continues to stand behind its formal target for 5% to 6% average annual sales growth through 2030. --- ## What It Means for Investors The magnitude of Tuesday's price action reflects how much value markets can assign to future pharmaceutical products before they generate commercial sales. Clinical failures can therefore alter expectations well before they affect reported revenue. That dynamic is especially relevant for Novartis because the company is dealing with falling Entresto sales and future patent expirations while using acquisitions to strengthen its development pipeline. Del-desiran is particularly important in that context because it came through the approximately $12 billion Avidity acquisition. Its failed primary endpoint therefore affects both expectations for the drug and investor assessment of the transaction that brought it into Novartis. The market reaction also extended beyond NVS stock. Dyne Therapeutics (DYN) and Sarepta Therapeutics (SRPT), which have exposure to treatments for muscular dystrophy, declined sharply as investors reassessed related therapeutic approaches. Amgen (AMGN) also fell after the pelacarsen failure raised questions surrounding Lp(a)-targeting cardiovascular drugs. The remaining clinical data now carry greater importance. Full pelacarsen results, regulatory feedback on del-desiran, findings from the rap-cel safety investigation and progress across Novartis' remaining programs will provide additional evidence about the strength of the broader pipeline. ## Conclusion Novartis' sharp selloff followed an unusually concentrated series of clinical setbacks. Del-desiran failed the primary endpoint of its Phase III HARBOR study shortly after pelacarsen failed to demonstrate reduced cardiovascular risk despite lowering Lp(a). Safety concerns have also resulted in pauses across most rap-cel studies. The setbacks arrive as Novartis faces pressure from Entresto's declining sales and future patent expirations, increasing the importance of successful new medicines. At the same time, the company has maintained its 5% to 6% average annual sales growth target through 2030, and several other development programs remain active. For the market, the focus now moves from the initial trial headlines to the underlying clinical data, regulatory feedback and whether the remaining pipeline can support Novartis' medium-term growth objectives. --- ## FAQs ### Why did Novartis stock fall? Novartis shares fell roughly 14% after del-desiran failed the primary endpoint of its Phase III HARBOR trial, adding to recent setbacks involving pelacarsen and rap-cel. ### What happened in the del-desiran Phase III trial? The approximately 150-patient HARBOR study did not show a statistically significant improvement over placebo in video hand opening time, its primary endpoint for patients with myotonic dystrophy type 1. ### What happened with Novartis' pelacarsen trial? Pelacarsen reduced Lp(a) levels in the 8,323-patient Phase III Lp(a)HORIZON study but failed to significantly reduce the composite risk of cardiovascular death, non-fatal heart attack, non-fatal stroke and urgent coronary revascularization requiring hospitalization versus placebo. ### Why is the del-desiran failure important for Novartis? Del-desiran was a centerpiece of Novartis' approximately $12 billion acquisition of Avidity Biosciences and had been viewed as a potential multibillion-dollar product, making the trial failure important to both the drug's outlook and assessment of the acquisition. ### Did Novartis change its 2030 sales growth target? No. Novartis maintained its target for average annual sales growth of 5% to 6% through 2030 despite the recent clinical setbacks. *This article was created with AI assistance and reviewed by an editor. For details, please refer to our* [*Terms of Use*](https://sharpertrades.com/p/terms?ref=brief.sharpertrades.com)*.* --- ### Go Beyond the Market Brief with Market Edge Follow SharperTrades’ complete approach to trading and investing, combining active trade opportunities through Block Orders, long-term research through Stock Investor, and structured market education through the Swing Trading Masterclass.[*Try Market Edge for $19 your first month →*](https://sharpertrades.com/p/market-edge?coupon%5Fcode=MB19&ref=brief.sharpertrades.com) ### Explore Research with Stock Investor [*Stock Investor*](https://sharpertrades.com/p/stock-investor/?ref=brief.sharpertrades.com) is SharperTrades’ platform for long-term investing research and portfolio management. Members receive research reports, portfolio updates, conviction tracking, and in-depth analysis designed to support disciplined investment decisions. ### Explore Active Trading & Income Strategies [*Block Orders*](https://sharpertrades.com/p/block-orders?coupon%5Fcode=MB1&ref=brief.sharpertrades.com) tracks institutional activity and highlights active trade setups and price behavior across long and short opportunities. For options-focused traders, [*Essential Option Income*](https://sharpertrades.com/p/option-alert-trading-signal?coupon%5Fcode=MB1&ref=brief.sharpertrades.com) provides a structured approach to options income strategies, while [*Pro Option Trader*](https://sharpertrades.com/p/pro-option-alert-trading-signal?coupon%5Fcode=MB19&ref=brief.sharpertrades.com) offers a broader range of options strategies and trade opportunities. ### Think More Clearly with SteadyCapital [SteadyCapital](https://studio.com/luca/steadycapital?c=fVDR9OI2&ref=brief.sharpertrades.com) is SharperTrades’ decision-support system for long-term investors, built around the SteadyCapital Method™. Review investment ideas, challenge assumptions, evaluate valuation and risk, compare companies, and think through important buy, hold, add, trim, or sell decisions before you act. ### Risk Disclosure All content is provided for educational purposes only and does not constitute investment advice. Trading involves risk, and past performance is not indicative of future results. Please review our full [Risk Disclosure](https://sharpertrades.com/p/risk-disclaimer?ref=brief.sharpertrades.com) for additional information.